抗血管生成剂于晚期和复发性宫颈癌的临床研究  

Clinical Study of Antiangiogenic Agents in Advanced and Recurrent Cervical Cancer

作　　者：胡婷婷 李海萍[2] 

机构地区：[1]青海大学研究生院,青海 西宁 [2]青海大学附属医院妇科肿瘤外科,青海 西宁

出　　处：《临床医学进展》2023年第3期3889-3894,共6页Advances in Clinical Medicine

摘　　要：宫颈癌的发病率和死亡率在全球恶性肿瘤居第四位。宫颈癌的主要治疗方式包括手术及放化疗,晚期和复发性患者虽采用化疗为主的个体化治疗,但治疗效果的有限,病情迅速恶化并死亡。联合应用抗血管生成剂可阻止肿瘤进展,提高患者的生存期,为晚期和复发性宫颈癌的治疗提供新思路,本文将抗血管生成剂对宫颈癌的作用机制和相关临床试验进展作一综述。Cervical cancer has the fourth highest incidence and mortality rate in the world for malignant tu-mors. The main treatment methods of cervical cancer include surgery and chemoradiotherapy, and although advanced and recurrent patients use chemotherapy-based individualized treatment, the treatment effect is limited, and the disease deteriorates rapidly and dies. The combined use of antiangiogenic agents can prevent tumor progression, improve the survival of patients, and provide new ideas for the treatment of advanced and recurrent cervical cancer. This article reviews the mechanism of action of antiangiogenic agents on cervical cancer and the progress of related clinical trials.

关 键 词：宫颈癌 抗血管生成剂 

分 类 号：R73[医药卫生—肿瘤]